Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 2:17:1557-1564.
doi: 10.2147/OPTH.S388293. eCollection 2023.

Spotlight on Schlemm's Canal MicroStent Injection in Patients with Glaucoma

Isabella V Wagner  1 , Bryan Ang  2 , Leticia Checo  1 , Derya Simsek  3 , Christian Draper  1 , Syril Dorairaj  1
Affiliations
Review

Spotlight on Schlemm's Canal MicroStent Injection in Patients with Glaucoma

Isabella V Wagner et al. Clin Ophthalmol. .

Abstract

Minimally invasive glaucoma surgery (MIGS) has revolutionized glaucoma care with its favorable safety profile and ability to delay or minimize the need for traditional, bleb-based procedures. Microstent device implantation is a type of angle-based MIGS, which reduces intraocular pressure (IOP) through bypass of the juxtacanalicular trabecular meshwork (TM) and facilitation of aqueous outflow into the Schlemm's canal. Although there are limited microstent devices on the market, multiple studies have evaluated the safety and efficacy of iStent® (Glaukos Corp.), iStent Inject® (Glaukos Corp.), and Hydrus® Microstent (Alcon) in the treatment of mild-to-moderate open-angle glaucoma, with and without concurrent phacoemulsification. This review attempts to provide a comprehensive evaluation of injectable angle-based microstent MIGS devices in the treatment of glaucoma.

Keywords: Hydrus microstent; Schlemm’s canal; aqueous outflow; glaucoma; iStent; microstent injection.

PubMed Disclaimer

Conflict of interest statement

Dr Bryan Ang is a consultant for and reports research and speaker’s honorariums from Glaukos Corporation and Alcon, Inc., outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Intraoperative photos of: (A) iStent inject (B) iStent inject W (C) Hydrus Microstent, showing positioning of the inlet in the anterior chamber. Courtesy of Bryan Ang.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults-screening, diagnosis, and management: a review. JAMA. 2021;325(2):164–174. PMID: 33433580. doi:10.1001/jama.2020.21899 - DOI - PubMed
    1. Wagner IV, Stewart MW, Dorairaj SK. Updates on the diagnosis and management of glaucoma. Mayo Clin Proc Innov Qual Outcomes. 2022;6(6):618–635. PMID: 36405987; PMCID: PMC9673042. doi:10.1016/j.mayocpiqo.2022.09.007 - DOI - PMC - PubMed
    1. Zhao Z, Zhu X, He W, Jiang C, Lu Y. Schlemm’s canal expansion after uncomplicated phacoemulsification surgery: an optical coherence tomography study. Invest Ophthalmol Vis Sci. 2016;57(15):6507–6512. PMID:27918824. doi:10.1167/iovs.16-20583 - DOI - PubMed
    1. Allison K, Patel D, Alabi O. Epidemiology of Glaucoma: the Past, Present, and Predictions for the Future. Cureus. 2020;12(11):e11686. PMID: 33391921; PMCID: PMC7769798. doi:10.7759/cureus.11686 - DOI - PMC - PubMed
    1. Mathew DJ, Buys YM. Minimally invasive glaucoma surgery: a critical appraisal of the literature. Annu Rev Vis Sci. 2020;6:47–89. PMID: 32936738. doi:10.1146/annurev-vision-121219-081737 - DOI - PubMed